Cargando…
Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer Berlin Heidelberg
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669414/ https://www.ncbi.nlm.nih.gov/pubmed/34924749 http://dx.doi.org/10.1186/s41983-021-00428-8 |
| _version_ | 1784614775036051456 |
|---|---|
| author | Siddiqui, Gulnaz Maloni, Heidi Nava, Victor E. |
| author_facet | Siddiqui, Gulnaz Maloni, Heidi Nava, Victor E. |
| author_sort | Siddiqui, Gulnaz |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8669414 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Springer Berlin Heidelberg |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86694142021-12-14 Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod Siddiqui, Gulnaz Maloni, Heidi Nava, Victor E. Egypt J Neurol Psychiatr Neurosurg Letter to the Editor Springer Berlin Heidelberg 2021-12-14 2021 /pmc/articles/PMC8669414/ /pubmed/34924749 http://dx.doi.org/10.1186/s41983-021-00428-8 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Letter to the Editor Siddiqui, Gulnaz Maloni, Heidi Nava, Victor E. Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod |
| title | Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod |
| title_full | Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod |
| title_fullStr | Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod |
| title_full_unstemmed | Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod |
| title_short | Adequate antibody response to BioNTech COVID vaccine in a multiple sclerosis patient treated with siponimod |
| title_sort | adequate antibody response to biontech covid vaccine in a multiple sclerosis patient treated with siponimod |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669414/ https://www.ncbi.nlm.nih.gov/pubmed/34924749 http://dx.doi.org/10.1186/s41983-021-00428-8 |
| work_keys_str_mv | AT siddiquigulnaz adequateantibodyresponsetobiontechcovidvaccineinamultiplesclerosispatienttreatedwithsiponimod AT maloniheidi adequateantibodyresponsetobiontechcovidvaccineinamultiplesclerosispatienttreatedwithsiponimod AT navavictore adequateantibodyresponsetobiontechcovidvaccineinamultiplesclerosispatienttreatedwithsiponimod |